Background: Massive strides have been made with respect to primary and secondary prevention of human papillomavirus (HPV)-associated disease as a result of prophylactic vaccination and cervical screening based on molecular HPV testing. However, cervical cancer continues to be an important clinical and societal burden. Additionally, other HPV-associated cancers, for which there are no screening programmes, are rising. Finally, the optimal combination of vaccination and screening strategies will require careful thinking. Considering this unprecedented and important time, we were keen to solicit the views of the expert community to determine what they perceived were the key priorities for HPV research. Our objective was to identify consensus and key priorities for HPV-based research through provision of a questionnaire disseminated to a multidisciplinary group of key opinion leaders (KOLs). Summary: A structured survey composed of 46 HPV research “categories” was sent to 73 KOLs who were invited to “rank” the categories according to priority. The invitees represented clinical and public health disciplines as well as basic scientists. Scores were weighted according to the number of responses. Invitees also had the opportunity to comment on barriers to the research and suggest other research areas that required attention not reflected in the survey. We received 29 responses in total; overall, the 3 highest-ranked categories were “optimal cervical screening in low and middle-income countries (LMICs),” “primary disease prevention in LMICs” and “impact of vaccine on HPV infection and associated disease.” “HPV and the microbiome” and “mechanisms of transformation” were the highest-ranked categories with respect to basic research. Consistent barriers to research were around governance on the use of samples and data and funding, particularly in an era of vaccination. Key Messages: Research to support the management of disease in LMICs is clearly perceived as a priority in the international community in addition to other diverse areas which necessitate an improved basic understanding of viral mechanisms and interactions. International, multidisciplinary efforts which articulate the broader HPV research agenda will be important when seeking funding in addition to international endeavours to support the efficient use of existing samples and cohorts to facilitate such research.

1.
Gissmann
L
,
Boshart
M
,
Dürst
M
,
Ikenberg
H
,
Wagner
D
,
zur Hausen
H
.
Presence of human papillomavirus in genital tumors
.
J Invest Dermatol
.
1984
Jul
;
83
(
1
Suppl
):
26s
8s
.
[PubMed]
0022-202X
2.
Syrjänen
KJ
,
Syrjänen
SM
.
Human papilloma virus (HPV) infections related to cervical intraepithelial neoplasia (CIN) and squamous cell carcinoma of the uterine cervix
.
Ann Clin Res
.
1985
;
17
(
2
):
45
56
.
[PubMed]
0003-4762
3.
Gissmann
L
.
Human papillomaviruses and genital cancer
[R]
.
Semin Cancer Biol
.
1992
Oct
;
3
(
5
):
253
61
.
[PubMed]
1044-579X
4.
zur Hausen
H
.
Papillomaviruses in the causation of human cancers - a brief historical account
.
Virology
.
2009
Feb
;
384
(
2
):
260
5
.
[PubMed]
0042-6822
5.
Poljak
M
,
Kocjan
BJ
,
Oštrbenk
A
,
Seme
K
.
Commercially available molecular tests for human papillomaviruses (HPV): 2015 update
.
J Clin Virol
.
2016
Mar
;
76
Suppl 1
:
S3
13
.
[PubMed]
1386-6532
6.
Mirabello
L
,
Clarke
MA
,
Nelson
CW
,
Dean
M
,
Wentzensen
N
,
Yeager
M
, et al.;
NCI HPV Workshop
.
The Intersection of HPV Epidemiology, Genomics and Mechanistic Studies of HPV-Mediated Carcinogenesis
.
Viruses
.
2018
Feb
;
10
(
2
):
E80
.
[PubMed]
1999-4915
7.
Mezei
AK
,
Armstrong
HL
,
Pedersen
HN
,
Campos
NG
,
Mitchell
SM
,
Sekikubo
M
, et al.
.
Cost-effectiveness of cervical cancer screening methods in low- and middle-income countries: A systematic review
.
Int J Cancer
.
2017
Aug
;
141
(
3
):
437
46
.
[PubMed]
0020-7136
8.
Hussein
AA
,
Helder
MN
,
de Visscher
JG
,
Leemans
CR
,
Braakhuis
BJ
,
de Vet
HC
, et al.
.
Global incidence of oral and oropharynx cancer in patients younger than 45 years versus older patients: A systematic review
.
Eur J Cancer
.
2017
Sep
;
82
:
115
27
.
[PubMed]
0959-8049
9.
Carlander
AF
,
Grønhøj Larsen
C
,
Jensen
DH
,
Garnæs
E
,
Kiss
K
,
Andersen
L
, et al.
.
Continuing rise in oropharyngeal cancer in a high HPV prevalence area: A Danish population-based study from 2011 to 2014
.
Eur J Cancer
.
2017
Jan
;
70
:
75
82
.
[PubMed]
0959-8049
10.
Nedjai
B
,
Reuter
C
,
Ahmad
A
,
Banwait
R
,
Warman
R
,
Carton
J
, et al.
.
Molecular progression to cervical precancer, epigenetic switch or sequential model
.
Int J Cancer
.
2018
Apr
;
143
(
7
):
1720
30
. ;
Epub ahead of print
.
[PubMed]
0020-7136
11.
Kriek
JM
,
Jaumdally
SZ
,
Masson
L
,
Little
F
,
Mbulawa
Z
,
Gumbi
PP
, et al.
.
Female genital tract inflammation, HIV co-infection and persistent mucosal Human Papillomavirus (HPV) infections
.
Virology
.
2016
Jun
;
493
:
247
54
.
[PubMed]
0042-6822
12.
Bosch
FX
,
Robles
C
,
Díaz
M
,
Arbyn
M
,
Baussano
I
,
Clavel
C
, et al.
.
HPV-FASTER: broadening the scope for prevention of HPV-related cancer
.
Nat Rev Clin Oncol
.
2016
Feb
;
13
(
2
):
119
32
.
[PubMed]
1759-4774
13.
Landy
R
,
Windridge
P
,
Gillman
MS
,
Sasieni
PD
.
What cervical screening is appropriate for women who have been vaccinated against high risk HPV? A simulation study
.
Int J Cancer
.
2018
Feb
;
142
(
4
):
709
18
.
[PubMed]
0020-7136
14.
Pedersen
K
,
Burger
EA
,
Nygård
M
,
Kristiansen
IS
,
Kim
JJ
.
Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: the value of stratifying guidelines
.
Eur J Cancer
.
2018
Mar
;
91
:
68
75
.
[PubMed]
0959-8049
15.
Canfell
K
.
Cervical screening in HPV-vaccinated populations
.
Climacteric
.
2018
Jun
;
21
(
3
):
227
34
.
[PubMed]
1369-7137
16.
Canfell
K
,
Saville
M
,
Caruana
M
,
Gebski
V
,
Darlington-Brown
J
,
Brotherton
J
, et al.
.
Protocol for Compass: a randomised controlled trial of primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25-69 years living in Australia
[Erratum in: BMJ Open. 2018 Mar 8;8] [3] [:e016700corr1]
.
BMJ Open
.
2018
Jan
;
8
(
1
):
e016700
.
[PubMed]
2044-6055
17.
Cuschieri
K
,
Ronco
G
,
Lorincz
A
,
Smith
L
,
Ogilvie
G
,
Mirabello
L
, et al.
.
Eurogin roadmap 2017: triage strategies for the management of HPV-positive women in cervical screening programs
.
Int J Cancer
.
2018
Aug
;
143
(
4
):
735
45
.
[PubMed]
0020-7136
18.
Lam
JU
,
Rebolj
M
,
Møller Ejegod
D
,
Pedersen
H
,
Rygaard
C
,
Lynge
E
, et al.
.
Human papillomavirus self-sampling for screening nonattenders: opt-in pilot implementation with electronic communication platforms
.
Int J Cancer
.
2017
May
;
140
(
10
):
2212
9
.
[PubMed]
0020-7136
19.
Enerly
E
,
Bonde
J
,
Schee
K
,
Pedersen
H
,
Lönnberg
S
,
Nygård
M
.
Self-Sampling for Human Papillomavirus Testing among Non-Attenders Increases Attendance to the Norwegian Cervical Cancer Screening Programme
.
PLoS One
.
2016
Apr
;
11
(
4
):
e0151978
.
[PubMed]
1932-6203
20.
Verdoodt
F
,
Jentschke
M
,
Hillemanns
P
,
Racey
CS
,
Snijders
PJ
,
Arbyn
M
.
Reaching women who do not participate in the regular cervical cancer screening programme by offering self-sampling kits: a systematic review and meta-analysis of randomised trials
.
Eur J Cancer
.
2015
Nov
;
51
(
16
):
2375
85
.
[PubMed]
0959-8049
21.
Lim
AW
,
Hollingworth
A
,
Kalwij
S
,
Curran
G
,
Sasieni
P
.
Offering self-sampling to cervical screening non-attenders in primary care
.
J Med Screen
.
2017
Mar
;
24
(
1
):
43
9
.
[PubMed]
0969-1413
22.
Pathak
N
,
Dodds
J
,
Zamora
J
,
Khan
K
.
Accuracy of urinary human papillomavirus testing for presence of cervical HPV: systematic review and meta-analysis
.
BMJ
.
2014
Sep
;
349
sep16 12
:
g5264
.
[PubMed]
0959-8138
23.
Van Keer
S
,
Tjalma
WA
,
Pattyn
J
,
Biesmans
S
,
Pieters
Z
,
Van Ostade
X
, et al.
.
Human papillomavirus genotype and viral load agreement between paired first-void urine and clinician-collected cervical samples
.
Eur J Clin Microbiol Infect Dis
.
2018
May
;
37
(
5
):
859
69
.
[PubMed]
0934-9723
24.
Leinonen
MK
,
Schee
K
,
Jonassen
CM
,
Lie
AK
,
Nystrand
CF
,
Rangberg
A
, et al.
.
Safety and acceptability of human papillomavirus testing of self-collected specimens: A methodologic study of the impact of collection devices and HPV assays on sensitivity for cervical cancer and high-grade lesions
.
J Clin Virol
.
2018
Feb - Mar
;
99-100
:
22
30
.
[PubMed]
1386-6532
25.
Stanczuk
G
,
Baxter
G
,
Currie
H
,
Lawrence
J
,
Cuschieri
K
,
Wilson
A
, et al.
.
Clinical validation of hrHPV testing on vaginal and urine self-samples in primary cervical screening (cross-sectional results from the Papillomavirus Dumfries and Galloway-PaVDaG study)
.
BMJ Open
.
2016
Apr
;
6
(
4
):
e010660
.
[PubMed]
2044-6055
26.
Palmer
TJ
,
McFadden
M
,
Pollock
KG
,
Kavanagh
K
,
Cuschieri
K
,
Cruickshank
M
, et al.
.
HPV immunisation and cervical screening—confirmation of changed performance of cytology as a screening test in immunised women: a retrospective population-based cohort study
.
Br J Cancer
.
2016
Mar
;
114
(
5
):
582
9
.
[PubMed]
0007-0920
27.
Bhatia
R
,
Kavanagh
K
,
Cubie
HA
,
Serrano
I
,
Wennington
H
,
Hopkins
M
, et al.
.
Use of HPV testing for cervical screening in vaccinated women—Insights from the SHEVa (Scottish HPV Prevalence in Vaccinated Women) study
.
Int J Cancer
.
2016
Jun
;
138
(
12
):
2922
31
.
[PubMed]
0020-7136
28.
De Strooper
LM
,
Berkhof
J
,
Steenbergen
RD
,
Lissenberg-Witte
BI
,
Snijders
PJ
,
Meijer
CJ
, et al.
.
Cervical cancer risk in HPV-positive women after a negative FAM19A4/mir124-2 methylation test: A post hoc analysis in the POBASCAM trial with 14 year follow-up
.
Int J Cancer
.
2018
Sep
;
143
(
6
):
1541
8
.
[PubMed]
0020-7136
29.
Lorincz
AT
.
Virtues and Weaknesses of DNA Methylation as a Test for Cervical Cancer Prevention
.
Acta Cytol
.
2016
;
60
(
6
):
501
12
.
[PubMed]
0001-5547
30.
Kelly
HA
,
Chikandiwa
A
,
Warman
R
,
Segondy
M
,
Sawadogo
B
,
Vasiljevic
N
, et al.
.
Associations of human gene EPB41L3 DNA methylation and cervical intraepithelial neoplasia in women living with HIV-1 in Africa
.
AIDS
.
2018
Sep
;
32
(
15
):
2227
36
.
[PubMed]
0269-9370
31.
Luttmer
R
,
De Strooper
LM
,
Dijkstra
MG
,
Berkhof
J
,
Snijders
PJ
,
Steenbergen
RD
, et al.
.
FAM19A4 methylation analysis in self-samples compared with cervical scrapes for detecting cervical (pre)cancer in HPV-positive women
.
Br J Cancer
.
2016
Aug
;
115
(
5
):
579
87
.
[PubMed]
0007-0920
32.
Meijer
CJ
,
Berkhof
J
,
Castle
PE
,
Hesselink
AT
,
Franco
EL
,
Ronco
G
, et al.
.
Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older
.
Int J Cancer
.
2009
Feb
;
124
(
3
):
516
20
.
[PubMed]
0020-7136
33.
Gallagher
KE
,
LaMontagne
DS
,
Watson-Jones
D
.
Status of HPV vaccine introduction and barriers to country uptake
.
Vaccine
.
2018
Aug
;
36
(
32
32 Pt A
):
4761
7
.
[PubMed]
0264-410X
34.
Sabeena
S
,
Bhat
PV
,
Kamath
V
,
Arunkumar
G
.
Global human papilloma virus vaccine implementation: an update
.
J Obstet Gynaecol Res
.
2018
Jun
;
44
(
6
):
989
97
.
[PubMed]
1341-8076
35.
Harper
DM
,
DeMars
LR
.
HPV vaccines - A review of the first decade
[Erratum in: Gynecol Oncol. 2017 Nov;147] [2]
.
Gynecol Oncol
.
2017
Jul
;
146
(
1
):
196
204
.
[PubMed]
0090-8258
36.
Jit
M
,
Brisson
M
.
Potential lives saved in 73 countries by adopting multi-cohort vaccination of 9-14-year-old girls against human papillomavirus
.
Int J Cancer
.
2018
Jul
;
143
(
2
):
317
23
.
[PubMed]
0020-7136
37.
Kreimer
AR
,
Struyf
F
,
Del Rosario-Raymundo
MR
,
Hildesheim
A
,
Skinner
SR
,
Wacholder
S
, et al.;
Costa Rica Vaccine Trial Study Group Authors
;
PATRICIA Study Group Authors
;
HPV PATRICIA Principal Investigators/Co-Principal Investigator Collaborators
;
GSK Vaccines Clinical Study Support Group
.
Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials
.
Lancet Oncol
.
2015
Jul
;
16
(
7
):
775
86
.
[PubMed]
1470-2045
38.
Sampson
JN
,
Hildesheim
A
,
Herrero
R
,
Gonzalez
P
,
Kreimer
AR
,
Gail
MH
.
Design and statistical considerations for studies evaluating the efficacy of a single dose of the human papillomavirus (HPV) vaccine
.
Contemp Clin Trials
.
2018
May
;
68
:
35
44
.
[PubMed]
1551-7144
39.
Franceschi
S
,
Clifford
GM
,
Baussano
I
.
Options for design of real-world impact studies of single-dose vaccine schedules
.
Vaccine
.
2018
Aug
;
36
(
32
32 Pt A
):
4816
22
.
[PubMed]
0264-410X
40.
Kavanagh
K
,
Pollock
KG
,
Cuschieri
K
,
Palmer
T
,
Cameron
RL
,
Watt
C
, et al.
.
Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study
.
Lancet Infect Dis
.
2017
Dec
;
17
(
12
):
1293
302
.
[PubMed]
1473-3099
41.
Korostil
IA
,
Ali
H
,
Guy
RJ
,
Donovan
B
,
Law
MG
,
Regan
DG
.
Near elimination of genital warts in Australia predicted with extension of human papillomavirus vaccination to males
.
Sex Transm Dis
.
2013
Nov
;
40
(
11
):
833
5
.
[PubMed]
0148-5717
42.
Cruickshank
ME
,
Pan
J
,
Cotton
SC
,
Kavanagh
K
,
Robertson
C
,
Cuschieri
K
, et al.
.
Reduction in colposcopy workload and associated clinical activity following human papillomavirus (HPV) catch-up vaccination programme in Scotland: an ecological study
.
BJOG
.
2017
Aug
;
124
(
9
):
1386
93
.
[PubMed]
1470-0328
43.
Corcoran
B
,
Clarke
A
,
Barrett
T
.
Rapid response to HPV vaccination crisis in Ireland
.
Lancet
.
2018
May
;
391
(
10135
):
2103
.
[PubMed]
0140-6736
44.
Maier
C
,
Maier
T
,
Neagu
CE
,
Vlădăreanu
R
.
Romanian adolescents’ knowledge and attitudes towards human papillomavirus infection and prophylactic vaccination
.
Eur J Obstet Gynecol Reprod Biol
.
2015
Dec
;
195
:
77
82
.
[PubMed]
0301-2115
45.
Suragh
TA
,
Lamprianou
S
,
MacDonald
NE
,
Loharikar
AR
,
Balakrishnan
MR
,
Benes
O
,
Hyde
TB
,
McNeil
MM
. Cluster anxiety-related adverse events following immunization (AEFI): An assessment of reports detected in social media and those identified using an online search engine. Vaccine.
2018
Aug 29. pii: S0264-410X(18)31203-9. [Epub ahead of print]
46.
Hanley
SJ
,
Yoshioka
E
,
Ito
Y
,
Kishi
R
.
HPV vaccination crisis in Japan. Lancet. 2015 Jun 27;385(9987):2571Erratum in
.
Lancet
.
2015
Jul
;
386
(
9990
):
248
.
[PubMed]
0140-6736
47.
Cheng MA, Farmer E, Huang C, Lin J, Hung CF Wu TC. Therapeutic DNA vaccines for human papillomavirus and associated diseases. Hum Gene Ther. 2018 Sep;29(9):971–96.
48.
Galliverti
G
,
Tichet
M
,
Domingos-Pereira
S
,
Hauert
S
,
Nardelli-Haefliger
D
,
Swartz
MA
,
Hanahan
D
,
Wullschleger
S
. Nanoparticle conjugation of human papillomavirus 16 E7-long peptides enhances therapeutic vaccine efficacy against solid tumors in mice. Cancer Immunol Res. 2018 Aug 21. pii: canimm.0166.
2018
. Epub ahead of print]
49.
Ilyinskii
PO
,
Kovalev
GI
,
O’Neil
CP
,
Roy
CJ
,
Michaud
AM
,
Drefs
NM
, et al.
.
Synthetic vaccine particles for durable cytolytic T lymphocyte responses and anti-tumor immunotherapy
.
PLoS One
.
2018
Jun
;
13
(
6
):
e0197694
.
[PubMed]
1932-6203
50.
Cordeiro
MN
,
De Lima
RC
,
Paolini
F
,
Melo
AR
,
Campos
AP
,
Venuti
A
, et al.
.
Current research into novel therapeutic vaccines against cervical cancer
.
Expert Rev Anticancer Ther
.
2018
Apr
;
18
(
4
):
365
76
.
[PubMed]
1473-7140
51.
Li
J
,
Chen
S
,
Ge
J
,
Lu
F
,
Ren
S
,
Zhao
Z
, et al.
.
A novel therapeutic vaccine composed of a rearranged human papillomavirus type 16 E6/E7 fusion protein and Fms-like tyrosine kinase-3 ligand induces CD8+ T cell responses and antitumor effect
.
Vaccine
.
2017
Nov
;
35
(
47
):
6459
67
.
[PubMed]
0264-410X
52.
Kyrgiou
M
,
Mitra
A
,
Moscicki
AB
.
Does the vaginal microbiota play a role in the development of cervical cancer
.
Transl Res
.
2017
Jan
;
179
:
168
82
.
[PubMed]
1931-5244
53.
Zhang
C
,
Liu
Y
,
Gao
W
,
Pan
Y
,
Gao
Y
,
Shen
J
, et al.
.
The direct and indirect association of cervical microbiota with the risk of cervical intraepithelial neoplasia
.
Cancer Med
.
2018
May
;
7
(
5
):
2172
9
.
[PubMed]
2045-7634
54.
Motevaseli
E
,
Shirzad
M
,
Akrami
SM
,
Mousavi
AS
,
Mirsalehian
A
,
Modarressi
MH
.
Normal and tumour cervical cells respond differently to vaginal lactobacilli, independent of pH and lactate
.
J Med Microbiol
.
2013
Jul
;
62
(
Pt 7
):
1065
72
.
[PubMed]
0022-2615
55.
Wang
KD
,
Xu
DJ
,
Wang
BY
,
Yan
DH
,
Lv
Z
,
Su
JR
.
Inhibitory Effect of Vaginal Lactobacillus Supernatants on Cervical Cancer Cells
.
Probiotics Antimicrob Proteins
.
2018
Jun
;
10
(
2
):
236
42
.
[PubMed]
1867-1306
56.
Wolf
A
,
Moissl-Eichinger
C
,
Perras
A
,
Koskinen
K
,
Tomazic
PV
,
Thurnher
D
.
The salivary microbiome as an indicator of carcinogenesis in patients with oropharyngeal squamous cell carcinoma: A pilot study
.
Sci Rep
.
2017
Jul
;
7
(
1
):
5867
.
[PubMed]
2045-2322
57.
Tainio
K
,
Athanasiou
A
,
Tikkinen
KA
,
Aaltonen
R
,
Cárdenas
J
,
Hernándes
, et al.
.
Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active surveillance: systematic review and meta-analysis
.
BMJ
.
2018
Feb
;
360
:
k499
.
[PubMed]
0959-8138
58.
Christensen
ND
,
Budgeon
LR
,
Cladel
NM
,
Hu
J
.
Recent advances in preclinical model systems for papillomaviruses
.
Virus Res
.
2017
Mar
;
231
:
108
18
.
[PubMed]
0168-1702
59.
Doorbar
J
.
Model systems of human papillomavirus-associated disease
.
J Pathol
.
2016
Jan
;
238
(
2
):
166
79
.
[PubMed]
0022-3417
60.
Cladel
NM
,
Budgeon
LR
,
Balogh
KK
,
Cooper
TK
,
Hu
J
,
Christensen
ND
.
A novel pre-clinical murine model to study the life cycle and progression of cervical and anal papillomavirus infections
.
PLoS One
.
2015
Mar
;
10
(
3
):
e0120128
.
[PubMed]
1932-6203
61.
Samuels
S
,
Balint
B
,
von der Leyen
H
,
Hupé
P
,
de Koning
L
,
Kamoun
C
, et al.
.
Precision medicine in cancer: challenges and recommendations from an EU-funded cervical cancer biobanking study
.
Br J Cancer
.
2016
Dec
;
115
(
12
):
1575
83
.
[PubMed]
0007-0920
You do not currently have access to this content.